DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Dent disease type 2 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDent disease type 2 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dent disease type 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
OCRL inositol polyphosphate-5-phosphatase (OCRL) — OCRL is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3QBT · 2.0 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
A Review of Clinical Follow-up Studies Focusing on Pretreatment Conditions of Abutment and Clinical Examination Parameters
AbstractPURPOSE: When patients have their teeth taken care of, one of their biggest concerns is how long the solution will last. Studies on the longevity or prognosis of bridges published so far have mainly reported on the evaluation of the survival rate for each kind of bridge. We believe that abutments need to be researched more carefully and clinically in the future. STUDY SELECTION: A Medline search was conducted, as well as manual searching of bibliographies from relevant articles. Studies reporting the survival rate were selected from the reports mentioning the prognosis of bridges. We mainly reviewed 1) the conditions of abutments before treatments and 2) applicable parameters in each case. RESULTS: We found no study that mentioned the detailed conditions of abutments before treatment using systematic evaluation parameters. Most parameters concerned the prosthodontics itself and bacteria. Only 21. 2% described objective parameters. CONCLUSION: This review indicates the necessity for establishing a classification of abutments based on some evidence so that the after-treatment conditions can be predicted from the pre-treatment conditions. It also indicates that we have to consider objective parameters carefully when conducting prospective research on the prognosis of fixed partial dentures or when establishing a new clinical evaluation system.
Improvement of Chewing Ability by Complete Denture: A Case Report
AbstractPATIENT: A 58 year-old female patient visited the clinic with chief complaint of chewing difficulty with her complete dentures. These dentures did not have a sufficient size of denture base and the resin teeth were completely ground down. Treatment dentures were inserted and the form was transferred to final dentures. DISCUSSION: The risk of re-treatment and adjustment after the denture insertion was reduced by using the treatment dentures. The Cochrane Library reported that there is no difference between complete dentures and implant supported over dentures in terms of patient satisfaction/chewing ability, provided the patient has an adequate mandibular ridge. CONCLUSION: Treatment dentures are important to reduce the risk of re-treatment.
Revista Metropolitana de Ciencias Aplicadas · 2023 · 0 citations · open access
Opciones de tratamiento ortopédico y ortodóntico en pacientes clase ii esqueletal en dentición mixta
AbstractSkeletal Class II is an anomaly that is frequently presented in orthodontic clinics. It represents approximately 51% of the total number of patients who come for consultation, its prevalence worldwide is 19%, with variations of 15% to 30% depending on the population. Treatment is varied and at a global level various proposals have been presented according to the age of each patient; however, there is controversy as to which method should be applied for each alteration present in the mixed dentition. The literature was selected by searching the following electronic databases: Pubmed, Lilacs, Google Academic, Epistemonikos, Elsevier, Springer. The search was for articles in English, Spanish and Portuguese published from January 2012 to January 2022. After applying the inclusion criteria, a total of 298 articles were obtained and reviewed, after which the articles were selected for analysis according to the selection criteria. The available literature revealed several treatment options for skeletal class II during mixed dentition, the results obtained are mostly dentoalveolar, the dento-skeletal changes are few, but contribute to great aesthetic improvements and in the patient's self-esteem.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
